30 patents
Page 2 of 2
Utility
Treatment of Lung Diseases Using Pharmaceutical Agents that Eliminate Senescent Cells
24 Jun 20
This invention is based on the discovery that many lung diseases associated with aging are mediated at least in part by cells bearing a senescent phenotype.
Nick Vlahakis, Scott Armstrong, Jamie Dananberg, Ryan Hudson, Anne-Marie Beausoleil, Nathaniel David, Remi-Martin Laberge
Filed: 12 Aug 18
Utility
Chemical Entities That Kill Senescent Cells for Use In Treating Age-related Disease
4 Mar 20
Disclosed herein are compounds that are effective for treatment of various disease states associated with senescence.
Nathaniel David
Filed: 19 Sep 19
Utility
Treating Cognitive Decline and Other Neurodegenerative Conditions by Selectively Removing Senescent Cells from Neurological Tissue
29 Jan 20
Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent.
Remi-Martin Laberge, Judith Campisi, Marco Demaria, Nathaniel David, James L. Kirkland, Tamar Tchkonia, Yi Zhu, Darren J. Baker, Jan M.A. van Deursen
Filed: 25 Sep 19
Utility
Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer
1 Jan 20
The proteasome inhibitors of this invention include peptide-based compounds with a short linear sequence of amino acids.
Ryan Hudson, Anne-Marie Beausoleil, F. Anthony Romero, Remi-Martin Laberge
Filed: 11 Aug 19
Utility
Acyl Sulfonamides that are BCL Family Antagonists for Use in Clinical Management of Conditions Caused or Mediated by Senescent Cells and for Treating Cancer
18 Dec 19
The aryl sulfonamide compounds of this invention have powerful and cell-type specific Bcl inhibitory activity.
Anne-Marie Beausoleil, Ryan Hudson
Filed: 18 Jun 19
Utility
Acyl Phosphonamidates and Acyl Benzylamines that are Bcl Family Antagonists for Use in Clinical Management of Conditions Caused or Mediated by Senescent Cells and for Treating Cancer
4 Dec 19
This disclosure provides compounds with Bcl inhibitory activity based on a new chemical scaffold.
Anne-Marie Beausoleil, Ryan Hudson
Filed: 28 May 19
Utility
Therapy for Removing Senescent Cells and Treating Senescence-associated Disease Using an MDM2 Inhibitor
13 Nov 19
Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent.
Remi-Martin Laberge, Judith Campisi, Albert Davalos, Marco Demaria, Nathaniel David, Alain Philippe Vasserot, James L. Kirkland, Tamar Tchkonia, Jennifer Elisseeff, Chaekyu Kim, Okhee Jeon, Yi Zhu
Filed: 9 Jul 19
Utility
Phosphonamidates that are Bcl Family Antagonists for Use in Clinical Management of Conditions Caused or Mediated By Senescent Cells and for Treating Cancer
30 Oct 19
This disclosure provides compounds with Bcl inhibitory activity based on a new chemical scaffold.
Anne-Marie Beausoleil, Ryan Hudson
Filed: 28 May 19
Utility
Phospholidines that are Bcl Family Antagonists for Use in Clinical Management of Conditions Caused or Mediated By Senescent Cells and for Treating Cancer
30 Oct 19
This disclosure provides compounds with Bcl inhibitory activity based on a new chemical scaffold.
Anne-Marie Beausoleil, Ryan Hudson
Filed: 28 May 19
Utility
Composition Comprising a Gene Vector That Selectively Depletes P16 Positive Senescent Cells
16 Oct 19
Polypeptides, viruses, methods and compositions provided herein are useful for the selective elimination of senescent cells.
Serge Lichtsteiner, Nathaniel David
Filed: 9 Jun 19